According to recent progress of cancer immunotherapy, in addition to the blockade of PD-L1/PD-1 interaction, the inhibition of PD-L1 expression in cancer cells constitutes an alternative to augment the antitumor immunity activity and further inhibited tumor growth (7, 8, 32). The gene discussed is PDCD1; the disease is cancer.